Koers Impax Laboratories Inc Nasdaq
Aandelen
US45256B1017
Farmaceutische producten
Omzet 2024 * | 2,6 mld. 2,43 mld. | Omzet 2025 * | 2,73 mld. 2,55 mld. | Marktkapitalisatie | 1,81 mld. 1,69 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 14 mln. 13,09 mln. | Nettowinst (verlies) 2025 * | 22 mln. 20,58 mln. | EV/omzet 2024 * | 1,58 x |
Nettoschuld 2024 * | 2,29 mld. 2,14 mld. | Nettoschuld 2025 * | 2,07 mld. 1,94 mld. | EV/omzet 2025 * | 1,42 x |
K/w-verhouding 2024 * |
117
x | K/w-verhouding 2025 * |
65,2
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 26,94% |
Recentste transcriptie over Impax Laboratories Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chirag K. Patel
FOU | Founder | 57 | 01-01-02 |
Chintu Patel
FOU | Founder | 53 | 01-01-02 |
Director of Finance/CFO | 57 | 07/11 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ted Nark
BRD | Director/Board Member | 66 | 07/11 |
J. Buchi
BRD | Director/Board Member | 69 | 07/11 |
Paul Meister
CHM | Chairman | 71 | 07/11 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 661 mld. | |
+27,00% | 566 mld. | |
-6,76% | 352 mld. | |
+20,34% | 332 mld. | |
+3,00% | 283 mld. | |
+13,09% | 231 mld. | |
+5,46% | 200 mld. | |
-9,61% | 195 mld. | |
-6,26% | 145 mld. |